Search results for "epidermal growth factor"

showing 10 items of 227 documents

Characterization of EGF-guided MDA-MB-231 cell chemotaxis in vitro using a physiological and highly sensitive assay system

2018

Chemotactic cell migration is a central mechanism during cancer cell invasion and hence metastasis. In order to mimic in vivo conditions, we used a three-dimensional hydrogel matrix made of collagen I and a stable gradient-generating chemotaxis assay system, which is commercially available (μ-Slide Chemotaxis) to characterize epidermal growth factor (EGF)-induced chemotaxis of the human breast cancer cell line MDA-MB-231. Surprisingly, chemotactic effects of EGF on MDA-MB-231 cells could neither be observed in the standard growth medium DMEM/F-12 supplemented with 10% serum nor in starvation medium. In contrast, after adapting the cells to the serum-free growth medium UltraCULTURETM, signif…

0301 basic medicinelcsh:MedicineBreast Neoplasms03 medical and health sciences0302 clinical medicineEpidermal growth factorIn vivoCell Line TumorHumansNeoplasm Metastasislcsh:ScienceReceptorMultidisciplinaryEpidermal Growth FactorTissue ScaffoldsChemistryChemotaxislcsh:RHydrogelsCell migrationChemotaxisPeptide FragmentsCulture MediaCell biologyErbB Receptors030104 developmental biologyCell culture030220 oncology & carcinogenesisCancer celllcsh:QCollagenChemotaxis assayPLOS ONE
researchProduct

Recombinant mussel protein Pvfp-5β: A potential tissue bioadhesive

2019

During their lifecycle, many marine organisms rely on natural adhesives to attach to wet surfaces for movement and self-defence in aqueous tidal environments. Adhesive proteins from mussels are biocompatible and elicit only minimal immune responses in humans. Therefore these proteins have received increased attention for their potential applications in medicine, biomaterials and biotechnology. The Asian green mussel Perna viridis secretes several byssal plaque proteins, molecules that help anchor the mussel to surfaces. Among these proteins, protein-5β (Pvfp-5β) initiates interactions with the substrate, displacing interfacial water molecules before binding to the surface. Here, we establis…

0301 basic medicinemedicine.disease_causeBiochemistryepidermal growth factor (EGF)law.inventionMiceCell Movementlawbiophysicsstructural biologyrecombinantCells CulturedbiologyChemistryMarine proteinsAdhesionRecombinant ProteinsadhesionProtein Structure and FoldingRecombinant DNAadhesion proteinsbiomaterialsPernaCell SurvivalSurface PropertiesBioadhesivemussel03 medical and health sciencesmedicineAnimalsHumansMolecular BiologyEscherichia coliCell ProliferationTissue Engineering030102 biochemistry & molecular biologyProteinsCell BiologyMusselbiology.organism_classificationEGF-like motifs; Marine proteins; adhesion; adhesion proteins; biomaterials; biophysics; epidermal growth factor (EGF); structural biologyEGF-like motifs030104 developmental biologyStructural biologyCell cultureNIH 3T3 CellsBiophysicsTissue AdhesivesHeLa CellsPerna viridisJournal of Biological Chemistry
researchProduct

Echovirus 1 infection depends on biogenesis of novel multivesicular bodies

2011

Summary Non-enveloped picornavirus echovirus 1 (EV1) clusters its receptor α2β1 integrin and causes their internalization and accumulation in α2β1 integrin enriched multivesicular bodies (α2-MVBs). Our results here show that these α2-MVBs are distinct from acidic late endosomes/lysosomes by several criteria: (i) live intra-endosomal pH measurements show that α2-MVBs are not acidic, (ii) they are not positive for the late endosomal marker LBPA or Dil-LDL internalized to lysosomes, and (iii) simultaneous stimulation of epidermal growth factor receptor (EGFR) and α2β1 integrin clustering leads to their accumulation in separate endosomes. EGFR showed downregulation between 15 min and 2 h, where…

0303 health sciencesbiologyEndosomemedia_common.quotation_subject030302 biochemistry & molecular biologyImmunologyIntegrinmacromolecular substancesMicrobiology3. Good healthCell biology03 medical and health sciencesDownregulation and upregulationVirologybiology.proteinTSG101Epidermal growth factor receptorReceptorInternalizationBiogenesis030304 developmental biologymedia_commonCellular Microbiology
researchProduct

Surface plasmon resonance signal enhancement based on erlotinib loaded magnetic nanoparticles for evaluation of its interaction with human lung cance…

2021

Abstract Surface plasmon resonance (SPR) sensor provides a very useful tool based on its label-free, real-time monitoring and low price properties. However, measurement of small molecules and extremely diluted analytes is difficult and therefore, signal enhancement is required. In the present study, signal enhancement of erlotinib conjugated magnetic nanoparticles (erlotinib-MNPs) compared to erlotinib was evaluated via their interaction with overexpressed epidermal growth factor receptor on human lung cancer cells (A549 cell line) surface using SPR sensor at three temperature levels. The attained results showed an average signal amplification of about 2.5-fold for MNP-erlotinib interaction…

A549 cellbiologyChemistry010401 analytical chemistry02 engineering and technologyConjugated system021001 nanoscience & nanotechnology01 natural sciencesSmall moleculeAtomic and Molecular Physics and Opticsrespiratory tract diseases0104 chemical sciencesElectronic Optical and Magnetic MaterialsCancer cellmedicinebiology.proteinBiophysicsMagnetic nanoparticlesErlotinibEpidermal growth factor receptorElectrical and Electronic EngineeringSurface plasmon resonance0210 nano-technologymedicine.drugOptics & Laser Technology
researchProduct

Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells

2019

Abstract Background Cucurbitacin E (CuE) is an oxygenated tetracyclic triterpenoid isolated from the fruits of Citrullus colocynthis (L.) Schrad. Purpose This study outlines CuE's cytotoxic activity against drug-resistant tumor cell lines. Three members of ABC transporters superfamily, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and ABCB5 were investigated, whose overexpression in tumors is tightly linked to multidrug resistance. Further factors of drug resistance studied were the tumor suppressor TP53 and the epidermal growth factor receptor (EGFR). Methods Cytotoxicity assays (resazurin assays) were used to investigate the activity of Citrullus colocynthis and CuE towar…

Abcg2Drug ResistancePharmaceutical ScienceATP-binding cassette transporterMicroarraySubfamily Gchemistry.chemical_compoundGene Knockout Techniques0302 clinical medicineEpidermal growth factorPhytogenicDrug DiscoveryATP Binding Cassette Transporter Subfamily G Member 2Cancer0303 health sciencesTumorLeukemiabiologyChemistryABCB5TransfectionCell cycleNeoplasm ProteinsGene Expression Regulation NeoplasticErbB ReceptorsMolecular Docking SimulationSubfamily B030220 oncology & carcinogenesisMolecular MedicineCitrullus colocynthiMember 2Member 1ATP Binding Cassette Transporter Subfamily BATP Binding Cassette TransporterAntineoplastic AgentsCell Line03 medical and health sciencesCell Line TumorHumansATP Binding Cassette Transporter Subfamily B Member 1030304 developmental biologyCucurbitacin EPharmacologyNeoplasticTraditional herbal medicineCancer; Citrullus colocynthis; Drug resistance; Microarray; Traditional herbal medicine; ATP Binding Cassette Transporter Subfamily B; ATP Binding Cassette Transporter Subfamily B Member 1; ATP Binding Cassette Transporter Subfamily G Member 2; Antineoplastic Agents Phytogenic; Cell Line Tumor; Citrullus colocynthis; Doxorubicin; Drug Resistance Neoplasm; ErbB Receptors; Gene Expression Regulation Neoplastic; Gene Knockout Techniques; Humans; Leukemia; Molecular Docking Simulation; Neoplasm Proteins; Triterpenes; Tumor Suppressor Protein p53Antineoplastic Agents PhytogenicTriterpenesComplementary and alternative medicineGene Expression RegulationDrug Resistance NeoplasmDoxorubicinCancer cellbiology.proteinCancer researchNeoplasmCitrullus colocynthisTumor Suppressor Protein p53
researchProduct

EGFR and PCNA experession in oral squamous cell carcinomas—a valuable tool in estimating the patient's prognosis

1993

We investigated 100 cases of oral squamous cell carcinomas immunohistologically with respect to the expression of the epidermal growth factor receptor (EGFR) and the proliferating cell nuclear antigen (PCNA). The results were correlated with a new malignancy grading of the invasive tumour areas and the clinical outcome of the patients to estimate the individual prognosis. In conclusion, the amount of antigen expression of both antigens increases with the increasing grade of malignancy of the oral squamous cell carcinoma. Furthermore, there is a statistically significant correlation between the amount of antigen expression and the patient's prognosis. An overexpression of EGFR and PCNA is as…

AdultCancer ResearchPathologymedicine.medical_specialtyMalignancyAntigenPredictive Value of TestsEpidermal growth factorProliferating Cell Nuclear AntigenBiomarkers TumormedicineHumansNeoplasm InvasivenessProspective StudiesEpidermal growth factor receptorSurvival analysisNeoplasm StagingMouth neoplasmbiologyPrognosismedicine.diseaseImmunohistochemistrySurvival AnalysisProliferating cell nuclear antigenErbB ReceptorsGene Expression Regulation Neoplasticstomatognathic diseasesTreatment OutcomeOncologyCarcinoma Squamous CellCancer researchbiology.proteinImmunohistochemistryMouth NeoplasmsEuropean Journal of Cancer Part B: Oral Oncology
researchProduct

ICAM-1 and α3β1 expression by bronchial epithelial cells and theirin vitromodulation by inflammatory and anti-inflammatory mediators

2000

Background: Adhesion molecules are involved in inflammatory and repair processes of the bronchial epithelium. ICAM-1 is mainly involved in inflammatory reactions, whereas integrins, such as α3β1, are mainly involved in repair processes. Methods: Using bronchial biopsies from 10 asthmatics and eight controls, we first evaluated by immunohistochemistry expression of α3β1 and ICAM-1 in intact and damaged epithelium. Then, using the human pulmonary epithelial cell line WI-26 VA, we studied, by flow-cytometry, the modulation of ICAM-1 and α3β1 expression, and, by ELISA, the release of fibronectin by proinflammatory cytokines, such as IL-5, and anti-inflammatory cytokines, such as IL-4, TGF-β, an…

AdultIntegrinsAdolescentBiopsyImmunologyIntegrinIntercellular Adhesion Molecule-1BronchiEnzyme-Linked Immunosorbent AssayInflammationRespiratory MucosaCell LineProinflammatory cytokineTransforming Growth Factor betamedicineHumansImmunology and AllergyAgedInflammationICAM-1Epidermal Growth FactorbiologyCell adhesion moleculeIntegrin alpha3beta1Epithelial CellsMiddle AgedFlow CytometryIntercellular Adhesion Molecule-1Molecular biologyAsthmaEpitheliumFibronectinsFibronectinmedicine.anatomical_structureImmunologybiology.proteinCytokinesInterleukin-4medicine.symptomAllergy
researchProduct

Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.

2014

Glioblastoma (GBM) is the most frequent and malignant primary brain tumor. Conventional therapy of surgical removal, radiation and chemotherapy is largely palliative. Major vault protein (MVP), the main component of the vault organelle has been associated with multidrug resistance by reducing cellular accumulation of chemotherapeutic agents. With regard to cancer, MVP has been shown to be overexpressed in drug resistance development and malignant progression. The aim of the present study was to evaluate the MVP gene dosage levels in 113 archival samples from GBM and its correlation with patients' survival and epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog (PTEN) …

AdultMaleBiologyGene dosageStatistics NonparametricYoung AdultMajor vault proteinmedicinePTENTensinHumansEpidermal growth factor receptorMultiplex ligation-dependent probe amplificationAgedVault Ribonucleoprotein ParticlesPolysomyBrain NeoplasmsGeneral NeurosciencePTEN PhosphohydrolaseCancerMiddle Agedmedicine.diseaseErbB ReceptorsGene Expression Regulation NeoplasticMutationCancer researchbiology.proteinFemaleGlioblastomaChromosomes Human Pair 7Neuroscience
researchProduct

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

2008

Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan. Experimental Design: Sixty-eight heavily pretreated metastatic colorectal cancer patients were evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and 1, 7, 14, 21, 50, and 92 days after the start of treatment. Results: Basal Mg2+ median levels were significan…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCetuximabmagnesiumcolorectal cancerAntibodies Monoclonal HumanizedIrinotecanGastroenterologyHypomagnesemiaBasal (phylogenetics)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMagnesiumEpidermal growth factor receptorNeoplasm MetastasisAgedAged 80 and overCetuximabbiologybusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseIrinotecanGene Expression Regulation NeoplasticEndocrinologyTreatment OutcomeOncologyMonoclonalbiology.proteinDisease ProgressionCamptothecinFemalebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epider…

2011

Purpose We conducted a phase I dose-escalation study to characterize the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic properties of RG7160 (GA201), a humanized and glycoengineered immunoglobulin G1 anti–epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity. Patients and Methods Seventy-five patients with advanced EGFR-positive solid tumors received RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks. Dose escalation followed a three-plus-three trial design. Results No maximum-tolerated dose was reached for any dosing schedule. Common adverse events (AEs) included rash (80% of patien…

AdultMaleCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroenterologyHypomagnesemiaCohort StudiesYoung AdultPharmacokineticsGrowth factor receptorNeoplasmsInternal medicineHumansMedicineDosingEpidermal growth factor receptorAdverse effectAgedGlycoproteinsAged 80 and overDose-Response Relationship Drugbiologybusiness.industryMiddle Agedmedicine.diseaseRashErbB ReceptorsOncologyPharmacodynamicsbiology.proteinFemalemedicine.symptombusinessJournal of Clinical Oncology
researchProduct